CAS 77671-31-9: Enoximone
Description:Enoximone is a pharmacological agent classified as a phosphodiesterase inhibitor, specifically targeting phosphodiesterase type III (PDE3). It is primarily used for its positive inotropic effects, which enhance cardiac contractility, making it beneficial in the treatment of heart failure. Enoximone works by increasing intracellular levels of cyclic adenosine monophosphate (cAMP), leading to improved myocardial function and vasodilation. The substance is typically administered intravenously and has a relatively short half-life, necessitating careful monitoring during treatment. Its chemical structure includes a pyridine ring and a ketone group, contributing to its biological activity. Enoximone is known for its potential side effects, which may include hypotension, arrhythmias, and gastrointestinal disturbances. Due to its specific action on the heart, it is often used in acute settings or for patients who do not respond adequately to conventional therapies. Overall, enoximone represents a valuable option in the pharmacological management of certain cardiac conditions, particularly in acute heart failure scenarios.
Formula:C12H12N2O2S
InChI:InChI=1/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)
InChI key:InChIKey=ZJKNESGOIKRXQY-UHFFFAOYSA-N
SMILES:O=C1NC(C(=O)C2=CC=C(SC)C=C2)=C(N1)C
- Synonyms:
- 1,3-Dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-one
- 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-
- 4-Methyl-5-[4-(methylsulfanyl)benzoyl]-1,3-dihydro-2H-imidazol-2-one
- 77671-31-9
- Fenoximone
- Mdl 17043
- Perfan
- Perfane
- Rmi 17043
